Jon Saxe - SciClone Pharmaceuticals Independent Chairman of the Board
Chairman
Mr. Jon S. Saxe J.D., is an Independent Chairman of the Board of SciClone Pharmaceuticals, Inc., since July 29, 2009. He has served as the Chairman of our Board of Directors since July 2009 and as a Director since August 2000. Mr. Saxe was President of PDL BioPharma, Inc. from 1995 to early 1999. From 1993 to 1995, Mr. Saxe was President of Saxe Associates, Inc., consultants to VC firms and biotechnology, diagnostic, and pharmaceutical companies. He was the President and CEO of Synergen, Inc., a biotechnology company acquired by Amgen, from 1989 to 1993. Mr. Saxe is former Vice President, Licensing and Corporationrationrate Development and Head of Patent Law for HoffmannLaRoche Inc., where he worked for almost 30 years since 2009.
| Age | 78 |
| Tenure | 15 years |
| Phone | 650 358-3456 |
| Web | www.sciclone.com |
Jon Saxe Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jon Saxe against SciClone Pharmaceuticals stock is an integral part of due diligence when investing in SciClone Pharmaceuticals. Jon Saxe insider activity provides valuable insight into whether SciClone Pharmaceuticals is net buyers or sellers over its current business cycle. Note, SciClone Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell SciClone Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jon Saxe over a month ago Acquisition by Jon Saxe of 12500 shares of VistaGen Therapeutics at 4.85 subject to Rule 16b-3 |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Rockell Hankin | Semtech | 70 | |
| Heber Bingham | Flex | 68 | |
| James Burra | Semtech | 74 | |
| Herber Bingham | Flex | 69 | |
| Thomas Dennis | FormFactor | 64 | |
| Braden Kelly | Fair Isaac | 50 | |
| George Battle | Fair Isaac | 74 | |
| Kyle Cerminara | BK Technologies | 40 | |
| Martin Heyningen | KVH Industries | 58 | |
| Valentin Gapontsev | IPG Photonics | 78 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Meng, VP of Compliance and General Counsel | ||
| Richard Hawkins, Independent Director | ||
| Gregg Lapointe, Independent Director | ||
| Hong Zhao, CEO of China Operations | ||
| Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
| Nancy Chang, Director | ||
| Anthony Lapointe, Independent Director | ||
| Lan Xie, VP of Fin. and CFO of China Operations | ||
| Raymond Low, Vice President - Finance, Controller | ||
| Robert King, Senior Vice President - Product Development and Supply Chain | ||
| Simon Li, Independent Director | ||
| Jon Saxe, Independent Chairman of the Board | ||
| Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 25.82 % | |||
| Current Valuation | 422 M | |||
| Shares Outstanding | 52.19 M | |||
| Shares Owned By Insiders | 10.03 % | |||
| Shares Owned By Institutions | 79.96 % | |||
| Number Of Shares Shorted | 1.21 M | |||
| Price To Earning | 13.75 X |
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |